Literature DB >> 26603524

TRK Inhibitor Shows Early Promise.

.   

Abstract

Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26603524     DOI： 10.1158/2159-8290.CD-NB2015-165

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  7 in total

1.  Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.

Authors:  Jaclyn F Hechtman; Ryma Benayed; David M Hyman; Alexander Drilon; Ahmet Zehir; Denise Frosina; Maria E Arcila; Snjezana Dogan; David S Klimstra; Marc Ladanyi; Achim A Jungbluth
Journal:  Am J Surg Pathol       Date:  2017-11       Impact factor: 6.394

2.  New targets bring hope in squamous cell lung cancer: neurotrophic tyrosine kinase gene fusions.

Authors:  Christian Rolfo; Luis Raez
Journal:  Lab Invest       Date:  2017-11       Impact factor: 5.662

3.  Clinical and Morphologic Features of ETV6-NTRK3 Translocated Papillary Thyroid Carcinoma in an Adult Population Without Radiation Exposure.

Authors:  Raja R Seethala; Simion I Chiosea; Cheng Z Liu; Marina Nikiforova; Yuri E Nikiforov
Journal:  Am J Surg Pathol       Date:  2017-04       Impact factor: 6.394

4.  Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms.

Authors:  Lu Wang; Klaus J Busam; Ryma Benayed; Robert Cimera; Jiajing Wang; Ryan Denley; Mamta Rao; Ruth Aryeequaye; Kerry Mullaney; Long Cao; Marc Ladanyi; Meera Hameed
Journal:  J Mol Diagn       Date:  2017-05       Impact factor: 5.568

5.  Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer.

Authors:  Jessica M Konen; B Leticia Rodriguez; Jared J Fradette; Laura Gibson; Denali Davis; Rosalba Minelli; Michael D Peoples; Jeffrey Kovacs; Alessandro Carugo; Christopher Bristow; Timothy Heffernan; Don L Gibbons
Journal:  Cancers (Basel)       Date:  2019-04-02       Impact factor: 6.639

6.  Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma.

Authors:  Rebecca Ronsley; S Rod Rassekh; Yaoqing Shen; Anna F Lee; Colleen Jantzen; Jessica Halparin; Catherine Albert; Douglas S Hawkins; Shazhan Amed; Ralph Rothstein; Andrew J Mungall; David Dix; Geoffrey Blair; Helen Nadel; Steven J M Jones; Janessa Laskin; Marco A Marra; Rebecca J Deyell
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02

Review 7.  Inhibiting TRK Proteins in Clinical Cancer Therapy.

Authors:  Allison M Lange; Hui-Wen Lo
Journal:  Cancers (Basel)       Date:  2018-04-04       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.